The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

for the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera MF or post essential ...

COPENHAGEN, Nov 14 (Reuters) - Norway's security service said on Thursday it had lowered the national threat assessment a notch to moderate from high. Norway on Oct. 8 raised its terrorism threat ...

The trial was designed to evaluate the safety and efficacy of momelotinib for treating and reducing key hallmarks of the disease: symptoms, blood transfusions (due to anemia) and splenomegaly. Results ...

Safety and efficacy results for SIMPLIFY-1 were based upon a subset of patients with moderate to severe anemia (haemoglobin <10 g/dL) at baseline. The efficacy of momelotinib in the treatment of ...

According to CPCB guidelines, "moderate" AQI affects those with respiratory conditions, while "poor" AQI causes widespread discomfort during extended exposure.

Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who have moderate to severe anemia and other key manifestations associated ...

Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who have moderate to severe anemia and other key manifestations associated with ...

Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer ...

Sickle cell anemia requires ongoing, lifelong treatment to improve quality of ... including transfusion-induced iron overload. Because the body does not have a way to get rid of iron received ...